Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Post-TAVR echocardiography helps predict a patient’s long-term risk of SVD
Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.
Pivotal trial highlights safety, effectiveness of FDA-approved carotid stent
The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.
Abbott’s Navitor TAVR valve linked to positive real-world outcomes
The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.
Heart teams playing a major role in coronary revascularization decisions
Sunil Rao, MD, discusses the heart team approach in the context of deciding what is best for the patient between bypass surgery and percutaneous coronary intervention.
Office-based interventional labs see boost in pay in 2026
CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

heart data research doctor cardiologist AI

Post-TAVR echocardiography helps predict a patient’s long-term risk of SVD

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.

CGuard Prime carotid stent system was cleared by the U.S. Food and Drug Administration (FDA) in June 2025.

Pivotal trial highlights safety, effectiveness of FDA-approved carotid stent

The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.

Abbott’s Navitor TAVR valve linked to positive real-world outcomes

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.

Sunil Rao, MD, director, interventional cardiology, cardiac catheterization laboratory, NYU Langone Heart, professor, Department of Medicine, the Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, discusses the heart team approach in the context to determining what is best for the patient in terms of bypass surgery or percutaneous coronary intervention.

Heart teams playing a major role in coronary revascularization decisions

Sunil Rao, MD, discusses the heart team approach in the context of deciding what is best for the patient between bypass surgery and percutaneous coronary intervention.

Hospital patient bays recovery Banner Health and Atlas Ambulatory Surgical Center (ASC) in Sun City, Arizona.

Office-based interventional labs see boost in pay in 2026

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

Boston Scientific to acquire Penumbra for $14.5B

This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions.

cardiologist patient heart compensation starting salary 2022 interventional cardiologist

TAVR’s next big challenge: Providing consistent relief for heart patients with aortic regurgitation

TAVR has already transformed care for patients with severe aortic stenosis. Will it make a similar impact on the treatment of aortic regurgitation?

Low-volume operators linked to worse outcomes after TAVR, M-TEER

Researchers tracked data from more than 400,00 patients, sharing their findings in JAMA Cardiology.